Temsirolimus: Is improved survival the correct expression of drug activity

Oncologist

Volumn 15, Issue 7, 2010, Pages 790-791

  Basso, Michele ^a   Cassano, Alessandra ^a   Schinzari, Giovanni ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH STATUS; HUMAN; KIDNEY CANCER; LETTER; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY NEOPLASMS; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 77956116948     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0099     Document Type: Letter

References (8)

1. Kwitkowski VE, Prowell TM, Ibrahim A et al. FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. The Oncologist 2010;15:428-435.
2. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
3. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373: 1119-1132.
4. Hudes G, Carducci M, Tomczak P. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR _ IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) [abstract LBA4]. J Clin Oncol 2006;24(18 suppl):2s.
5. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-8670.
6. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141.
7. Pyrhönen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-2867.
8. Dutcher JP, Szczylik C, Tannir P et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) [abstract 5033]. J Clin Oncol 2007;25: 243s.